Valiant Organics Q1 FY27 results: PAT up 188% YoY at Rs 21.8 cr

Pat Growth 25pctEbitda Margin ExpansionExceptional ItemRelated Party TransactionsResults View source PDF Explain this filing

VALIANTORG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹325.30

prior close

₹341.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%+4.8% vs market

Specialty Chemicals peers, median of 92sector+0.0%+5.0% vs sector

On the reaction day the stock moved 4.8 pts more than Nifty Microcap 250 and 5.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+0.2+4.8+0.0+5.0

Next day

-0.2+0.2-0.5+0.1-0.3

-5.2+0.4-5.6-0.7-4.5

-4.6+0.7-5.3-0.6-4.0

-2.9+0.1-3.0-1.1-1.8

-4.4+0.7-5.1-0.4-4.0

-9.0+1.2-10.2+0.1-9.1

15d

-2.8+0.7-3.6+1.7-4.5

+19.3-1.2+20.5-1.8+21.1

+38.9-1.1+40.1-1.6+40.6

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 92Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 unaudited results. Standalone revenue at Rs 231.5 cr, up 13% YoY. Net profit jumped 188% YoY to Rs 21.8 cr from Rs 7.6 cr. EPS at Rs 7.79 vs Rs 2.71. Pharma segment now reported separately with Rs 55.8 cr revenue. Also approved re-appointment of MD Sathiababu Kallada for 3 years and shifting of registered office to Tarapur.

Likely market impact

Strong profit growth on margin expansion and lower base. Pharma segment reporting adds clarity. Leadership continuity confirmed through 2030.